Literature DB >> 23083736

Genetic removal of p70 S6 kinase 1 corrects molecular, synaptic, and behavioral phenotypes in fragile X syndrome mice.

Aditi Bhattacharya1, Hanoch Kaphzan, Amanda C Alvarez-Dieppa, Jaclyn P Murphy, Philippe Pierre, Eric Klann.   

Abstract

Fragile X syndrome (FXS) is the leading inherited cause of autism and intellectual disability. Aberrant synaptic translation has been implicated in the etiology of FXS, but most lines of research on therapeutic strategies have targeted protein synthesis indirectly, far upstream of the translation machinery. We sought to perturb p70 ribosomal S6 kinase 1 (S6K1), a key translation initiation and elongation regulator, in FXS model mice. We found that genetic reduction of S6K1 prevented elevated phosphorylation of translational control molecules, exaggerated protein synthesis, enhanced mGluR-dependent long-term depression (LTD), weight gain, and macro-orchidism in FXS model mice. In addition, S6K1 deletion prevented immature dendritic spine morphology and multiple behavioral phenotypes, including social interaction deficits, impaired novel object recognition, and behavioral inflexibility. Our results support the model that dysregulated protein synthesis is the key causal factor in FXS and that restoration of normal translation can stabilize peripheral and neurological function in FXS.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23083736      PMCID: PMC3479445          DOI: 10.1016/j.neuron.2012.07.022

Source DB:  PubMed          Journal:  Neuron        ISSN: 0896-6273            Impact factor:   17.173


  65 in total

1.  Altered anxiety-related and social behaviors in the Fmr1 knockout mouse model of fragile X syndrome.

Authors:  C M Spencer; O Alekseyenko; E Serysheva; L A Yuva-Paylor; R Paylor
Journal:  Genes Brain Behav       Date:  2005-10       Impact factor: 3.449

2.  mTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events.

Authors:  Marina K Holz; Bryan A Ballif; Steven P Gygi; John Blenis
Journal:  Cell       Date:  2005-11-18       Impact factor: 41.582

3.  Hippocampal pyramidal cells in adult Fmr1 knockout mice exhibit an immature-appearing profile of dendritic spines.

Authors:  Aaron W Grossman; Nicholas M Elisseou; Brandon C McKinney; William T Greenough
Journal:  Brain Res       Date:  2006-03-30       Impact factor: 3.252

4.  Metabotropic receptor-dependent long-term depression persists in the absence of protein synthesis in the mouse model of fragile X syndrome.

Authors:  Elena D Nosyreva; Kimberly M Huber
Journal:  J Neurophysiol       Date:  2006-02-01       Impact factor: 2.714

5.  Dynamic translational and proteasomal regulation of fragile X mental retardation protein controls mGluR-dependent long-term depression.

Authors:  Lingfei Hou; Marcia D Antion; Daoying Hu; Corinne M Spencer; Richard Paylor; Eric Klann
Journal:  Neuron       Date:  2006-08-17       Impact factor: 17.173

Review 6.  The pathophysiology of fragile x syndrome.

Authors:  Olga Penagarikano; Jennifer G Mulle; Stephen T Warren
Journal:  Annu Rev Genomics Hum Genet       Date:  2007       Impact factor: 8.929

7.  Multiple Gq-coupled receptors converge on a common protein synthesis-dependent long-term depression that is affected in fragile X syndrome mental retardation.

Authors:  Lenora J Volk; Brad E Pfeiffer; Jay R Gibson; Kimberly M Huber
Journal:  J Neurosci       Date:  2007-10-24       Impact factor: 6.167

8.  Correction of fragile X syndrome in mice.

Authors:  Gül Dölen; Emily Osterweil; B S Shankaranarayana Rao; Gordon B Smith; Benjamin D Auerbach; Sumantra Chattarji; Mark F Bear
Journal:  Neuron       Date:  2007-12-20       Impact factor: 17.173

9.  Inhibition of p21-activated kinase rescues symptoms of fragile X syndrome in mice.

Authors:  Mansuo L Hayashi; B S Shankaranarayana Rao; Jin-Soo Seo; Han-Saem Choi; Bridget M Dolan; Se-Young Choi; Sumantra Chattarji; Susumu Tonegawa
Journal:  Proc Natl Acad Sci U S A       Date:  2007-06-25       Impact factor: 11.205

10.  A new function for the fragile X mental retardation protein in regulation of PSD-95 mRNA stability.

Authors:  Francesca Zalfa; Boris Eleuteri; Kirsten S Dickson; Valentina Mercaldo; Silvia De Rubeis; Alessandra di Penta; Elisabetta Tabolacci; Pietro Chiurazzi; Giovanni Neri; Seth G N Grant; Claudia Bagni
Journal:  Nat Neurosci       Date:  2007-04-08       Impact factor: 24.884

View more
  143 in total

Review 1.  mTOR in health and in sickness.

Authors:  Dritan Liko; Michael N Hall
Journal:  J Mol Med (Berl)       Date:  2015-09-22       Impact factor: 4.599

Review 2.  Genes, circuits, and precision therapies for autism and related neurodevelopmental disorders.

Authors:  Mustafa Sahin; Mriganka Sur
Journal:  Science       Date:  2015-10-15       Impact factor: 47.728

3.  Insulin-Like Growth Factor II Targets the mTOR Pathway to Reverse Autism-Like Phenotypes in Mice.

Authors:  Adam B Steinmetz; Sarah A Stern; Amy S Kohtz; Giannina Descalzi; Cristina M Alberini
Journal:  J Neurosci       Date:  2017-12-07       Impact factor: 6.167

Review 4.  Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome.

Authors:  Elizabeth M Berry-Kravis; Lothar Lindemann; Aia E Jønch; George Apostol; Mark F Bear; Randall L Carpenter; Jacqueline N Crawley; Aurore Curie; Vincent Des Portes; Farah Hossain; Fabrizio Gasparini; Baltazar Gomez-Mancilla; David Hessl; Eva Loth; Sebastian H Scharf; Paul P Wang; Florian Von Raison; Randi Hagerman; Will Spooren; Sébastien Jacquemont
Journal:  Nat Rev Drug Discov       Date:  2017-12-08       Impact factor: 84.694

5.  Elevated ERK/p90 ribosomal S6 kinase activity underlies audiogenic seizure susceptibility in fragile X mice.

Authors:  Kirsty Sawicka; Alexander Pyronneau; Miranda Chao; Michael V L Bennett; R Suzanne Zukin
Journal:  Proc Natl Acad Sci U S A       Date:  2016-09-23       Impact factor: 11.205

Review 6.  Experience and sleep-dependent synaptic plasticity: from structure to activity.

Authors:  Linlin Sun; Hang Zhou; Joseph Cichon; Guang Yang
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2020-04-06       Impact factor: 6.237

Review 7.  The translation of translational control by FMRP: therapeutic targets for FXS.

Authors:  Jennifer C Darnell; Eric Klann
Journal:  Nat Neurosci       Date:  2013-04-14       Impact factor: 24.884

8.  Pharmacological stimulation of the brain serotonin receptor 7 as a novel therapeutic approach for Rett syndrome.

Authors:  Bianca De Filippis; Paola Nativio; Alessia Fabbri; Laura Ricceri; Walter Adriani; Enza Lacivita; Marcello Leopoldo; Francesca Passarelli; Andrea Fuso; Giovanni Laviola
Journal:  Neuropsychopharmacology       Date:  2014-05-09       Impact factor: 7.853

9.  Neuron-Type Specific Loss of CDKL5 Leads to Alterations in mTOR Signaling and Synaptic Markers.

Authors:  Ethan Schroeder; Li Yuan; Eunju Seong; Cheryl Ligon; Nicholas DeKorver; C B Gurumurthy; Jyothi Arikkath
Journal:  Mol Neurobiol       Date:  2018-10-04       Impact factor: 5.590

Review 10.  Therapeutic approaches for shankopathies.

Authors:  Xiaoming Wang; Alexandra L Bey; Leeyup Chung; Andrew D Krystal; Yong-Hui Jiang
Journal:  Dev Neurobiol       Date:  2013-10-11       Impact factor: 3.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.